Taevas
United StatesPharmaceuticals
Legal Representation
Legal Representation for Pharmaceuticals in United States
Taevas Global provides dedicated legal representation for pharmaceutical manufacturers seeking to enter or expand in the United States, ensuring full FDA compliance and regulatory readiness from day one. Our specialists bridge the gap between your global
Market
United States
Industry
Pharmaceuticals
Service
Legal Representation
Regulator
FDA (Food and Drug Administration)
Timeline
6-12 weeks
What We Deliver
Six Pillars of United States Pharmaceuticals Intelligence
Our six interconnected pillars give pharmaceutical companies a complete legal and regulatory foundation for successful, compliant market entry into the United States.
01
FDA Regulatory Representation
We act as your official US Agent with the FDA, fulfilling the mandatory requirement for foreign drug manufacturers to have a designated domestic representative. Our team manages all FDA correspondence, inspections, and submissions on your behalf, ensuring no communication is missed or mishandled.
Designated US Agent registration with FDA
Management of FDA correspondence and notices
Coordination of facility inspection readiness
How It Works
From Brief to Board-Ready Intelligence
Our structured four-step engagement transforms your market entry goals into a fully documented, legally compliant roadmap for the United States pharmaceutical market.
Step 1 · Day 1-2
Discovery and Needs Assessment
We begin with a structured intake session to understand your product portfolio, target indications, manufacturing locations, and current regulatory status. This assessment identifies gaps in your US legal readiness and defines the scope of representation required. You receive a clear summary of obligations and timelines.
Taevas Approach
Our intake process covers FDA registration status, existing IND or NDA filings, facility compliance history, labeling assets, and IP holdings. We cross-reference your situation against current FDA enforcement priorities and import alert databases to flag any immediate risks before engagement begins.
Market Snapshot
United States Pharmaceuticals Market at a Glance
$0B
US Pharmaceutical Market Size (2023)
0%
Projected Annual Market Growth Rate
0+
FDA-Registered Foreign Drug Manufacturers
0+
New Drug Applications Filed Annually
World's Largest Pharmaceutical Market
The United States accounts for approximately 45 percent of global pharmaceutical revenues, making it the single most important market for drug manufacturers worldwide. The combination of premium pricing, large patient populations, and robust insurance coverage creates unmatched commercial opportunity for approved products. Foreign manufacturers represent a growing share of the US drug supply chain.
Rigorous FDA Enforcement Environment
The FDA issues hundreds of warning letters and import alerts annually to pharmaceutical manufacturers that fail to meet Current Good Manufacturing Practice standards. Foreign facilities face heightened scrutiny, with FDA conducting overseas inspections and placing non-compliant manufacturers on import alert lists that block product entry. Legal representation is essential for navigating and resolving enforcement actions.
Growing Generic and Biosimilar Opportunity
The Inflation Reduction Act and ongoing drug pricing reforms are accelerating demand for generic and biosimilar alternatives, with the FDA's ANDA approval rate reaching record highs in recent years. Generic drugs now account for approximately 90 percent of US prescriptions dispensed, creating significant entry opportunities for international manufacturers with compliant facilities. Biosimilar approvals have also surged following the Biologics Price Competition and Innovation Act framework.
Complex Multi-Jurisdictional Legal Landscape
Pharmaceutical companies operating in the United States must comply simultaneously with federal FDA and DEA regulations, state pharmacy board requirements, and payer-specific formulary rules across more than 50 jurisdictions. The legal complexity is compounded by evolving state drug pricing transparency laws and opioid litigation precedents that affect distribution practices. Specialized legal representation is the most effective risk mitigation strategy for foreign market entrants.
What's Included
Everything in Your Report
Each Legal Representation engagement for the United States pharmaceutical market includes these eight core deliverables, giving your team a complete compliance and market entry foundation.
FDA Registration and US Agent Designation
Complete execution of FDA facility registration and official US Agent designation filed through the FDA Industry Systems portal, with confirmation documentation provided to your team.
Regulatory Pathway Assessment Report
A written analysis of the optimal FDA approval pathway for each product in your US portfolio, including timeline estimates, fee schedules, and key submission milestones.
Labeling and Promotional Compliance Review
Line-by-line review of all product labeling and promotional materials against 21 CFR Parts 201 and 202, with a gap report and revised draft language where corrections are needed.
Intellectual Property Strategy Memorandum
A structured IP memorandum covering Hatch-Waxman patent considerations, Orange Book listing strategy, and recommended actions to protect your product exclusivity in the US market.
State Licensing Roadmap
A state-by-state licensing matrix identifying all required pharmacy board, drug distributor, and DEA registrations for your target US distribution footprint, with application timelines and fee summaries.
FDA Correspondence Management Protocol
A documented protocol for routing, reviewing, and responding to all FDA communications, including a defined escalation process for inspection notices and enforcement correspondence.
Pharmacovigilance and Adverse Event Reporting Framework
A compliance framework aligning your existing pharmacovigilance processes with FDA adverse event reporting requirements under 21 CFR Part 314.81 and MedWatch obligations.
Ongoing Regulatory Monitoring and Briefings
Monthly regulatory intelligence briefings covering FDA guidance updates, enforcement trends, and legislative developments relevant to your US pharmaceutical portfolio, delivered in executive summary format.
Who This Is For
Built for These Situations
Market Entry
Foreign Pharmaceutical Manufacturer Entering the US
Your company manufactures branded or generic drugs outside the United States and is preparing to register products with the FDA for the first time. You need a legally designated US Agent, a clear regulatory pathway, and expert guidance to avoid the import alerts and warning letters that derail many first-time US entrants. Taevas Global handles every step of the legal registration and compliance process so your team can focus on commercial readiness.
Outcome
Achieve FDA registration and US Agent designation within six weeks, with a documented compliance roadmap for your first product submission.
Next Steps
After Legal Representation, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your United States Opportunity?
Connect with a Taevas Global pharmaceutical legal specialist today to discuss your US market entry strategy and get a tailored legal representation proposal within 48 hours.
FDA-registered US Agent designation handled end-to-end
Regulatory pathway assessment for your full product portfolio
State licensing roadmap across all target US jurisdictions
Ongoing FDA correspondence management and compliance monitoring